|
Nigeria Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Nigeria Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Nigeria.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Nigerian pharmaceutical and healthcare industry.
Competitive intelligence, Nigerian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Nigerian market.
The Nigeria Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Nigeria Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Nigerian pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Nigeria to test other views – a key input for successful budgeting and strategic business planning in the Nigerian pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Nigerian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Nigeria.
- Exploit The Latest Competitive Nigerian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Nigeria.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Nigeria Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| SWOT Analysis |
| Nigeria Pharmaceuticals And Healthcare Industry SWOT |
| Nigeria Political SWOT |
| Nigeria Economic SWOT |
| Nigeria Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Middle East And Africa Pharmaceutical Business Environment Ratings |
| Limits To Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Market Summary |
| Regulatory Regime |
| Import Regime |
| Recent Regulatory Developments |
| Intellectual Property Regime |
| Counterfeit Drugs |
| Recent Developments in Regards to Counterfeit Drugs |
| Pricing And Reimbursement Regime |
Chapter - Industry Developments |
| Epidemiology |
| Table: Leading Causes Of Death In Africa, 2002 |
| HIV/AIDS |
| Healthcare Sector |
| Healthcare Provision |
| Recent Healthcare Sector Developments |
| Healthcare Reforms |
| Health Insurance |
| Traditional African Medicine |
| Domestic Pharmaceutical Sector |
| Foreign Pharmaceutical Sector |
| National Drug Policy |
| Research and Development |
| Medical Devices |
| Recent Developments In The Medical Devices Market |
| Table: Nigeria Free Zones: Key Incentives |
Chapter - Industry Forecast Scenario |
| Overall Market Forecasts |
| Table: Nigeria – Drug Market Expenditure, 2003-2013 |
| Key Growth Factors – Industry |
| Table: Nigeria – Health Expenditure, 2003-2013 |
| Key Growth Factors – Macroeconomic |
| Table: Nigeria - Economic Activity |
| Prescription Drug Market Forecast |
| Table: Nigeria's – Prescription Drug Market, 2003-2013 (NGNmn unless otherwise stated) |
| OTC Drug Market Forecast |
| Table: Nigeria – OTC Market Data Forecasts, 2003-2013 (NGNmn unless otherwise stated) |
| Patented Drug Market Forecast |
| Table: Nigeria – Patented Drug Market Indicators, 2003-2013 |
| Generic Drug Market Forecast |
| Table: Nigeria – Generic Drug Market Indicators, 2003-2013 |
| Export/Import Market Forecasts |
| Table: Nigeria – Pharmaceutical Trade Balance, 2003-2013 |
| Other Healthcare Data Forecasts |
| Table: Nigeria – Other Health Indicators, 2003-2013 |
| Key Risks To BMI's Forecasts |
Chapter - Competitive Landscape |
| Company Profiles |
| Multinationals |
| Pfizer |
| Novartis |
| Sanofi-Aventis |
| GlaxoSmithKline (GSK) |
| Indigenous Producers |
| Nigeria-German Chemicals PLC (NGC) |
| Emzor |
| Fidson Healthcare |
| Archy |
| Neros Pharmaceuticals |
| Drugfield Pharmaceuticals Limited |
| Neimeth |
| BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
Chapter - Country Snapshot: Nigeria Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Nigeria Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
For this Q209 Pharmaceutical and Healthcare Nigeria report, BMI has forecast that the total drug market will increase from US$633mn in 2008 to US$695mn by 2013, representing a compound annual growth rate (CAGR) of 1.89% in US dollar terms and 3.24% with respect to the Nigerian naira. We believe the main drivers for growth are the various healthcare programmes that have been implemented to increase health awareness and primary care uptake. The promotion of the national health insurance scheme (NHIS) is expected to see renewed drive from the government to boost pharmaceutical spending. Underlining this, we expect healthcare expenditure to rise from US$7.3bn in 2008 to US$8.3bn by 2013.
During December 2008 the teething syrup My Pikin raised alarm when the National Agency for Food, Drug Administration and Control (NAFDAC) confirmed that over 29 infants had died after using it. This has now increased to 80 victims. Barewa Pharmaceuticals, an indigenous drug manufacturer which produced My Pikin, has been shut down, while the owner of Nigerian chemical supplier Tranxell has been arrested and accused of providing the illegal and toxic compound diethylene glycol which was used in producing the syrup. Diethylene glycol is normally found in anti-freeze and brake fluid.
Nigeria's pharmaceutical industry has been damaged by counterfeiting since its independence in 1960. While poor intellectual property (IP) protection and financial mismanagement deters multinational drug companies from releasing patented drugs, it also questions the integrity of indigenous manufacturers. The lack of transparency and compliance in the Nigerian drug industry will not instil confidence into the system, especially at a time when the country is trying to discourage or ban imported medicines in order to promote self-sufficiency.
In January 2009, the health minister of Nigeria, Babatunde Osotimehin, announced that the government will release more funds into the NHIS to encourage rural communities to participate. While low income, poor healthcare access in remote areas and illiteracy form the basis for non-compliance, BMI believes that the government and the NHIS should co-ordinate efforts in educating the rural population about health insurance.
|
Nigeria Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |